CombiMatrix | GenomeWeb

CombiMatrix

The company can now market the test in New York, in addition to other areas of the country where it has already made the assay available.

The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.

CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.

The company said its total test volume went up 7 percent during the quarter, including a 9 percent increase in the number of reproductive health tests performed.

The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.

The company's NGS-based PGS test will initially join, and eventually replace, its current array-based CombiPGS option, which it launched in 2014.

The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter. 

The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.

The firm will offer 8,000 units of Series F convertible stock at $1,000 each, and plans to use the proceeds to repurchase and retire its Series E stock.

The company said its revenue increase was driven by gains in test volume, particularly in miscarriage analysis and preimplantation genetic screening for couples undergoing IVF.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.